Article
Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains.
Cancer letters - 28 Sept 2001
Stanley L A, Carthew P, Davies R, Higginson F, Martin E, Styles J A
Abstract excerpt
The anti-oestrogenic drug tamoxifen has been under investigation as a breast cancer chemopreventive agent for at least a decade. However, its use for this purpose is still debatable since it is able to induce liver tumours in rats via a mechanism involving metabolic activation to a DNA adduct-forming electrophilic intermediate. The metabolic activation and adduct-forming properties of tamoxifen are now well...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
